Recent innovations across the multiple ADC components, such as enhanced antibody-targeting to the tumors, better linker ...

A Roots Analysis study showed the market for ADC manufacturing is $1.79 billion today, but is expected to grow to $7 billion ...

Analysis of Antibody Drug Conjugates Contract Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan ROCKVILLE, MD, UNITED STATES, June 18, ...

NextCure gains global rights to SIM0505 excluding greater China, where Simcere Zaiming will retain rights; Phase 1 clinical ...

In this video, Sonali M. Smith, MD, discusses several notable studies on new treatment combinations and other options for ...

Medicovestor, Inc., a New York-based biotechnology company pioneering first-in-class chemoimmunotherapy antibody-drug ...

Amerigo Scientific offers PerKitsTM drug conjugation kits to simplify and optimize the conjugation of small-molecule drugs to biomolecules. NE ...

Results from a first-in-human Phase Ia/Ib trial show that LY4170156 demonstrated a notably high overall response rate in ...

Get Instant Summarized Text (Gist) Pivekimab sunirine (PVEK), a CD123-targeted antibody-drug conjugate, demonstrated an 85% overall response rate and 70% complete response rate as frontline ...

Bispecific antibody drug conjugates (BsADCs) are an innovative class of therapeutics that combine the dual-targeting capabilities of bispecific antibodies with the cytotoxic payloads ...

NextCure has ramped up its antibody-drug conjugate (ADC) pivot, penning a $745 million deal for the ex-China rights to ...

Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...